To Top

Pipeline

Overview

CM24 NTS219 MI1240

CM24

CM24 is a first-in-class, clinical-stage immune checkpoint inhibitor mAb targeting CEACAM1, with significant potential to treat multiple cancers.

NT219

NT219 is a first-in-class, novel small molecule targeting both IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.

IM1240

IM1240 is the lead tribody in development of our conditionally-activated tri-specific antibody platform which engages both T cells and NK cells and TAA.

IM1240 targets 5T4 as TAA (CD3x5T4xNKG2A)

 

Publications

NT219

CM24

Skip to content